Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inga Ludwig

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|May 23, 2022
Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence studyByron Jones, Bingbing Li, Morten Bagger, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 25, 2021
A framework to guide dose & regimen strategy for clinical drug developmentOliver Sander, Baldur Magnusson, Inga Ludwig, et al.
Neurology and Therapy|December 19, 2022
Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS TrialAmit Bar-Or, Xavier Montalban, Xixi Hu, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 4, 2021
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 studyAmit Bar-Or, Heinz Wiendl, Xavier Montalban, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|May 23, 2022
Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence studyByron Jones, Bingbing Li, Morten Bagger, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 25, 2021
A framework to guide dose & regimen strategy for clinical drug developmentOliver Sander, Baldur Magnusson, Inga Ludwig, et al.
Neurology and Therapy|December 19, 2022
Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS TrialAmit Bar-Or, Xavier Montalban, Xixi Hu, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 4, 2021
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 studyAmit Bar-Or, Heinz Wiendl, Xavier Montalban, et al.
Pageof 1